# Transposon systems for cell engineering

Source: https://onco.cc/terms/transposon/  
OnCo record `transposon` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An engineered DNA transposon is a gene-insertion system in which an enzyme, the transposase, places a designed cassette into a cell's DNA. A separate method has to deliver the pieces first, and non-viral does not mean non-integrating.

## Summary

A transposon system has two parts: a cargo cassette flanked by boundary sequences, and a transposase that recognises those boundaries and catalyses insertion. The transposase can be supplied as protein or through instructions that make it, and the cell has to receive both in usable form; the system does not itself deliver anything. Sleeping Beauty was reconstructed from inactive fish elements, and its transposase bound the inverted repeats and mediated precise cut-and-paste transposition in fish, mouse and human cells (Ivics and colleagues).

In one reported clinical example, two phase I trials in 26 people (7 autologous, 19 allogeneic) electroporated peripheral blood mononuclear cells with Sleeping Beauty transposon and transposase plasmids encoding a CD19-specific CAR and expanded them on activating and propagating cells for a median of 28 days. The abstract reports 2,200 to 2,500-fold ex vivo expansion, 84 per cent CAR expression, no integration hotspots, no acute or late toxicities reported, and CAR T-cell persistence averaging 201 days in autologous and 51 days in allogeneic recipients; the discussion states that the products were free of detectable SB11 transposase (Kebriaei and colleagues). That is a feasibility and safety report in small uncontrolled trials, and it describes cells engineered outside the body, not injected components.

Systems differ. In primary human T cells from peripheral blood and cord blood, piggyBac gave the highest stable gene transfer efficiency in the peripheral-blood cells and the most integrants in both, Tol2 and piggyBac were more likely to promote clonal expansion than Sleeping Beauty, and Tol2 and piggyBac integrated near transcription start sites and CpG islands while Sleeping Beauty integrations looked random (Huang and colleagues). That is a laboratory comparison, not a ranking of safety in patients. Insertion-site sequencing recovers only some junctions: in the Sleeping Beauty trial's 33 independent libraries most shared fewer than 20 per cent of sites with any other library, which the authors read as arguing against common hotspots, although some pairs shared over 40 per cent and 100,000 of 571,533 unique integrations were mapped. That describes those libraries, not every insertion or later clone, and an average copy number hides differences between cells. FDA follow-up guidance states that integration by transposon elements is not directed to specific sites and that continuing transposase in target cells creates the potential for remobilising an inserted element, so transposase persistence and cassette persistence are separate measurements.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: DNA transposon; transposase; Sleeping Beauty transposon; piggyBac; nonviral gene insertion
- Tags: delivery-vehicle; gene-delivery

## Notes

- An inserted cassette can be copied with chromosomal DNA during cell division; that genetic persistence does not guarantee continued expression, cell survival or useful activity. Report insertion sites, copy-number denominator, receptor-positive cells, retained transposase and antigen-dependent function separately. A mean copy count cannot recover the distribution across cells or all insertion sites.

## Sources

- Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.: https://doi.org/10.1016/s0092-8674(00)80436-5
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.: https://doi.org/10.1172/jci86721
- Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells.: https://doi.org/10.1038/mt.2010.141
- Long Term Follow-Up After Administration of Human Gene Therapy Products: guidance for industry, January 2020: https://www.fda.gov/media/113768/download

## Connected records

- terms: [AAV (adeno-associated virus) vector](https://onco.cc/terms/aav-vector/), [Lentiviral vector](https://onco.cc/terms/lentiviral-vector/)
- ideas: [Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route](https://onco.cc/ideas/idea-reg-non-viral-cart-manufacturing/)
- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/), [Viral vector manufacturing (lentiviral, retroviral, AAV)](https://onco.cc/technologies/viral-vector-manufacturing/)

---
JSON: https://onco.cc/api/v1/entities/transposon.json